Adding a chimeric antigen receptor (CAR) to natural killer (NK) cells is garnering interest as a therapeutic strategy because this immune cell type doesn't cause graft-versus-host disease, making its widespread, off-the-shelf use feasible. Based on promising preclinical data, a phase I/II trial of one such CAR NK-cell therapy is under way, targeting CD19 in hematologic malignancies.

中文翻译：

---

为NK细胞配备汽车

将嵌合抗原受体（CAR）添加到自然杀伤（NK）细胞作为一种治疗策略引起了人们的兴趣，因为这种免疫细胞类型不会引起移植物抗宿主病，从而使其广泛，现成的使用成为可能。基于有希望的临床前数据，一项针对此类CAR NK细胞疗法的I / II期试验正在进行中，该疗法针对血液系统恶性肿瘤中的CD19。